Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 13 of 6351
-
New gene therapy hopes to restore milestones in rett syndrome
Disease control OngoingThe primary objectives of this study are to evaluate the safety of a single intrathecal (IT) dose of TSHA-102 in females with typical Rett syndrome, to select the TSHA-102 dose with the best benefit/risk profile based on the totality of safety and efficacy data and to evaluate th…
Phase 3 • Sponsor: Taysha Gene Therapies, Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Womb transplant: a temporary fix for a permanent infertility?
Cure Recruiting nowThis research study will use uterus transplantation to treat uterine factor infertility, also known as the inability to bear children due to not having a uterus. The purpose of this study is to enable women seeking genetically-related children and the childbearing experience to e…
Phase 2/3 • Sponsor: Johns Hopkins University • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
-
Can a single molecule quiet the genetic chaos behind three brain diseases?
Disease control Recruiting nowThe goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's disease. Another aim is to determine the concentrat…
Phase 1/2 • Sponsor: Vico Therapeutics B. V. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
CAR-T therapy takes on High-Risk lymphoma as First-Line treatment
Disease control OngoingThe goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
Phase 3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can donor immune cells be engineered to fight blood cancer?
Cure Recruiting nowKCAT19 is a single-centre, non-randomised, open-label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age 16-65 years) with high risk, relapsed/refractory (r/r) B cell malignancies.
Phase 1 • Sponsor: University College, London • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
-
Hope for rare brain tumor: phase 3 trial of ONC201 launches
Disease control Recruiting nowThis is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline radiotherapy will extend overall survival…
Phase 3 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
One-Time gene therapy aims to restore muscle in boys with duchenne
Disease control OngoingRGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, …
Phase 2/3 • Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Bubble boy disease: gene therapy trial offers hope for immune system repair
Disease control OngoingThe aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from mobilized peripheral blood (mPB) of ADA-deficient SCID infants and children following human ADA gene transfer by the EFS-ADA lentiviral vector. …
Phase 1/2 • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a new antibody make stem cell transplants safer for CGD patients?
Cure OngoingBackground: Chronic granulomatous disease (CGD) is a rare immune disorder that can cause serious infections throughout the body. The only cure for CGD is a stem cell transplant. Transplants from a sibling are best, but many people must get transplants from unrelated donors. Howe…
Early phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Cure
Last updated Aug 29, 2026 00:00 UTC
-
New hope for babies with aggressive leukemia: international trial launches
Disease control Recruiting nowThis study is a treatment protocol with blinatumomab for infants under 1 year old who are diagnosed with acute lymphoblastic leukemia with a specific unfavorable genetic alteration. The purpose of the study is to improve the outcome of this disease in infants.
Phase 3 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Can engineered immune cells outsmart Drug-Resistant ovarian cancer?
Cure OngoingThis is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product. Backfill cohorts will enroll additional subjects at doses deemed to be safe for a total enrollment of up to 12 s…
Phase 1 • Sponsor: Arsenal Biosciences, Inc. • Aim: Cure
Last updated Sep 05, 2026 00:00 UTC
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
Cure OngoingThe purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Phase 1 • Sponsor: Arcellx, Inc. • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
-
Two-Drug combo aims to wipe out breast cancer before surgery in BRCA carriers
Cure Recruiting nowThis study is an open-label, single-arm, multicenter clinical study. 64 patients with germline BRCA-mutated HER2-negative early breast cancer are planned to be enrolled and treated with fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of neoad…
Phase 2 • Sponsor: Peking University People's Hospital • Aim: Cure
Last updated Jul 23, 2026 00:00 UTC
-
New hope for kids with DIPG: major trial compares two treatments
Disease control Recruiting nowThe BIOMEDE 2.0 study is the second stage of the BIOMEDE multi-arm, multistage rolling programme (adaptive platform protocol). It is a multicenter, randomized, open-label, controlled phase-3 trial evaluating efficacy of ONC201 in comparison with everolimus (primary objective bas…
Phase 3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can engineered immune cells outsmart Treatment-Resistant myeloma?
Cure Stopped earlyThis is a prospective, single-arm, open-label, dose-finding and dose-expansion study that evaluates the safety, tolerability, PK, and anti-tumor efficacy of LCAR-BCDR cell preparations in relapsed/refractory multiple myeloma subjects who received adequate standard therapy.
Phase 1 • Sponsor: Shanghai Changzheng Hospital • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
-
One-dose antibody slashes RSV hospitalizations in infants
Prevention CompletedThe purpose of this study was to determine the efficacy and safety of a single intramuscular (IM) dose of nirsevimab, compared to no intervention, for the prevention of hospitalizations due to lower respiratory tract infection (LRTI) caused by confirmed RSV infection (henceforth …
Phase 3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated Jun 27, 2026 07:54 UTC
-
Can a smart drug outperform chemo for Hard-to-Treat lung cancer?
Disease control OngoingDisease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile. There is an urgent need for more effective and tol…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Could ketamine be a fast-acting lifeline for suicidal teens and young adults?
Symptom relief Recruiting nowKetamine, an NMDA antagonist, has been shown to have rapid anti- suicidal effects. However, its safety and efficacy and special populations has not been investigated and documented. Several reports in adults suggest rapid decrease of suicidal ideation. In the last decade there is…
Phase 3 • Sponsor: Tatiana Falcone, MD • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
New 11-Valent HPV vaccine aims to block more Cancer-Causing viruses
Vaccine Recruiting nowA total of 13500 Chinese women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 35-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1. All subjects enrolled in the upper arm deltoid mus…
Phase 3 • Sponsor: National Vaccine and Serum Institute, China • Aim: Vaccine
Last updated Jun 27, 2026 08:12 UTC
-
CRISPR gene therapy aims to free kids from lifelong blood transfusions
Disease control OngoingThis is a single-dose, open-label study in pediatric participants with TDT. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).
Phase 3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC